The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

@inproceedings{Tejani2010TheCO,
  title={The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer},
  author={Mohamedtaki Abdulaziz Tejani and Roger B. Cohen and Ranee Mehra},
  booktitle={Biologics : targets & therapy},
  year={2010}
}
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy… CONTINUE READING
18 Citations
105 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 105 references

Similar Papers

Loading similar papers…